Lantheus Holdings, Inc. (NASDAQ:LNTH) had its target price lifted by stock analysts at Credit Suisse Group from $19.00 to $23.00 in a research note issued on Friday, November 3rd. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Credit Suisse Group’s target price suggests a potential upside of 0.88% from the stock’s current price.
A number of other equities analysts have also issued reports on LNTH. BidaskClub lowered Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Zacks Investment Research lowered Lantheus Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, September 20th. Jefferies Group LLC reissued a “buy” rating and issued a $22.00 price objective (up from $18.00) on shares of Lantheus Holdings in a report on Wednesday, August 2nd. Wells Fargo & Company raised Lantheus Holdings from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Finally, Cantor Fitzgerald assumed coverage on Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $24.50.
Shares of Lantheus Holdings (LNTH) traded down $0.60 during trading on Friday, hitting $22.80. The stock had a trading volume of 268,918 shares, compared to its average volume of 560,381. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. The firm has a market cap of $855.14 and a PE ratio of 20.40. Lantheus Holdings has a fifty-two week low of $7.95 and a fifty-two week high of $24.10.
ILLEGAL ACTIVITY WARNING: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/credit-suisse-group-boosts-lantheus-holdings-inc-lnth-price-target-to-23-00/1756964.html.
In other news, Director David F. Burgstahler sold 91,166 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $17.01, for a total transaction of $1,550,733.66. Following the completion of the sale, the director now owns 13,248 shares in the company, valued at approximately $225,348.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Timothy G. Healey sold 11,314 shares of the stock in a transaction on Friday, November 17th. The shares were sold at an average price of $21.51, for a total value of $243,364.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 644,638 shares of company stock valued at $11,079,593. 2.30% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. Marshall Wace North America L.P. lifted its holdings in shares of Lantheus Holdings by 1,214.5% in the second quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock valued at $18,975,000 after purchasing an additional 973,977 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Lantheus Holdings by 87.5% in the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock valued at $26,093,000 after purchasing an additional 689,954 shares in the last quarter. State Street Corp lifted its holdings in shares of Lantheus Holdings by 3,932.8% in the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after purchasing an additional 601,714 shares in the last quarter. Peregrine Capital Management LLC purchased a new stake in shares of Lantheus Holdings in the third quarter valued at $8,062,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Lantheus Holdings in the second quarter valued at $7,396,000. Institutional investors own 89.25% of the company’s stock.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with our FREE daily email newsletter.